Since his second time period began, President Donald Trump has introduced, negotiated, or floated a flurry of initiatives aimed toward taming the excesses of the pharmaceutical business.
No shock. About 60% of American adults are “frightened about having the ability to afford prescription drug prices for themselves or their households,” a latest KFF nationwide ballot confirmed. Greater than 80% think about the value of pharmaceuticals “unreasonable,” and most help elevated regulation to decrease prices. People pay about thrice as a lot as folks in different nations for a similar pharmaceuticals.
Final July, Trump despatched letters to 17 drugmakers, demanding they voluntarily decrease drug costs. Then the president stated he’d negotiated with greater than a dozen pharmaceutical executives one after the other on the White Home. In December, he introduced that he had compelled them to comply with “most favored nation” pricing on Medicaid, the federal government protection for low-income People.
Then got here the unveiling of TrumpRxa website the place cash-paying sufferers might discover discounted medicines, and a promise to hurry biosimilar merchandise — generic variations of sure high-priced specialty medicine — by reducing by FDA purple tape.
The scope of those grand gestures stays unsure. But it surely’s definitely lower than what the announcement promised, partly as a result of many particulars of the negotiations, even which medicine are coated, are hazy.
White Home spokesperson Kush Desai didn’t reply queries about TrumpRx.
Medicaid already buys medicine at deep reductions. And different sufferers might effectively have higher choices by industrial drug low cost packages, which supply much more merchandise, or by their insurance coverage and related drug firm copayment playing cards.
So, for all Trump’s showmanship, the share of People prone to profit from these choices stays slim, even when some folks do come out forward.
“If it makes a distinction to any affected person, it’s a win,” stated Mark Cuban, a billionaire investor on his personal mission to deliver down drug costs. He pointed to discounted pricing on TrumpRx for branded fertility medicine and GLP-1 weight reduction medicine for folks with out insurance coverage or whose plans don’t embrace protection. Cuban launched the Mark Cuban Value Plus Drug Co., generally known as Value Plus Medication, in 2022 to promote medicine cheaply by eliminating middlemen — shopping for from factories and promoting on to shoppers. Many of the medicine he sells are generics.
Aaron Kesselheim, a professor of drugs at Harvard Medical Faculty whose analysis focuses on drug costs, stated the Trump bulletins are “one-off agreements made for publicity functions. They don’t change something about the best way medicine are priced.”
He added: “The agreements are opaque and unenforceable.”
It was unclear, for instance, which medicine could be offered at “most favored nation” costs or how precisely that was outlined. However, clearly, not all have been.
Doing the Math
46brooklyn, a consulting agency and knowledge mission that tracks brand-name drug costs, discovered that near 1,000 model medicine went up in value in January 2026. What’s extra, 2025 had the best variety of record value will increase ever. “This isn’t a cloth change, it’s enterprise as typical,” stated Antonio Ciaccia, the corporate’s co-founder.
Within the first week of 2026, Pfizer raised the record costs of 71 medicine by a mean of 5% and lowered the value of just one, by 9.8%, the info mission discovered.
The largest win for sufferers has possible been the Trump administration’s quiet continuation of a Biden administration program: Medicare drug value negotiation for costly medicine. The negotiated reductions on the preliminary 10 medicine — from blood thinners to insulins to medicines for inflammatory problems — went into impact Jan. 1. With reductions in value of effectively over 50% on some merchandise, the estimated $6 billion in annual financial savings allowed this system to cap Medicare sufferers’ out-of-pocket spending on Half D pharmaceuticals at $2,000 for 2025 and past.
An extra 15 high-priced medicine — together with well-liked weight reduction and most cancers medicine — have been topic to negotiation in 2025, with discounted Medicare costs taking impact subsequent 12 months. And 15 extra high-priced medicine are set for negotiation this 12 months. All instructed, the 40 negotiated drug costs are anticipated to avoid wasting Medicare effectively over $20 billion a 12 months.
At the same time as these reductions take impact, drug business lobbyists have been working to restrict the influence, with some success. For instance, the One Huge Stunning Invoice Act exempts medicine for uncommon ailments from negotiations.
Nonetheless, “that is historic as a result of it’s the primary time the US has negotiated costs, like each different developed nation,” Kesselheim stated. “And guess what? Innovation didn’t cease.”
In fact, these reductions profit solely Medicare enrollees. The newer Trump administration initiatives assist another sufferers, however they’re restricted and require data of the best way to entry the reductions.
Trump’s One-on-Ones
The president’s televised appearances with the heads of main drug corporations resulted in offers, however few, if any, will imply a lot to sufferers. For instance, after Trump met with Albert Bourla, CEO of Pfizer, the corporate introduced reductions on 30-plus medicine. Bourla referred to as the deal “a win for American sufferers, a win for American management, and a win for Pfizer.”
The reductions are provided through TrumpRx, which, in flip, provide coupons co-branded on GoodRx.com, which already affords low cost coupons for a lot of tons of of medicines.
Pfizer made hay of the deal, saying it was a part of Pfizer’s broader, landmark most favored nation, or MFN, settlement with the U.S. authorities, enabling sufferers to pay decrease costs for his or her prescription medicines “whereas strengthening America’s position as the worldwide chief in biopharmaceutical innovation.”
Pfizer spokesperson Steven Danehy cited a press launch from September noting that the TrumpRx website affords sufferers financial savings that “vary as excessive as 85%.”
Many of the record options brand-name medicine, competing with far cheaper generic variations from different producers, such because the cholesterol-lowering drug Colestid, which TrumpRx lists for “50% off” at $127.91. Generic variations price about $17 on the Value Plus website.
This implies the branded corporations aren’t making a sacrifice by providing them at decrease prices as mirrored on Trump’s portal, stated Sean Tu, a patent legislation professional on the College of Alabama. “That’s a sale they’d not have made if not for TrumpRx.”
Others are very outdated medicine, resembling Cortef, or hydrocortisone, whose 5-milligram branded Pfizer model is listed at $45 on TrumpRx, half its record value of $91.80. It sells for much much less on Cuban’s Value Plus website. Nonetheless others, such because the $607.20 HIV remedy Viracept, are helpful solely together with different medicine that aren’t discounted.
Final week, TrumpRx added Amgen’s Humira, for years the world’s best-selling drug, at $950 a dose, down from a listing value of practically $7,000. However Humira misplaced its patent safety in 2023, and biosimilars — basically generic equivalents — have since come to market. Extra to the purpose, two of these biosimilars are listed on TrumpRx for as little as $207.60 a dose.
Since a lot of the TrumpRx merchandise can be found solely to prospects with out insurance coverage who pay money, the arthritis drug Xeljanz’s drop from $2,277 to $1,518 a month would nonetheless depart it unaffordable.
A Few Notable Offers
The much-touted TrumpRx website, launched Feb. 6, consists largely of Pfizer’s 30 medicine (30 of roughly 85) with a smattering of reductions prone to generate headlines.
These embrace three fertility medicine from EMD Serono, a subsidiary of the pharmaceutical big Merck KGaA, the costliest of which, Gonal-F, has a listing value of $966 however is just $168 per IVF cycle utilizing a TrumpRx coupon.
They’ll save ladies hundreds of {dollars} — though the general price of fertility remedy will proceed to place them past the attain of many, since medicine characterize solely a portion of the cost.
The TrumpRx reductions might cut back the $15,000-to-$25,000 price of a single fertility remedy cycle — ladies sometimes want two or three cycles to change into pregnant — by about 10%, stated Sean Tipton, spokesperson for the American Society for Reproductive Drugs. In some European nations, every cycle prices about $3,000.
In change for decreasing these costs, EMD Serono received tariffs lifted on its largely overseas-produced medicines. It additionally received the best to a sped-up FDA approval course of for a fertility drug it’s been advertising and marketing closely in Europe.
One other newsworthy providing on the positioning resulted from a cope with Novo Nordisk for Wegovy, its GLP-1 drug for weight reduction and diabetes, with the value decreased to as little as $199 a month for the pen. (Many insurers cowl such medicine just for diabetes, leaving those that are fascinated by shedding weight paying out-of-pocket. Zepbound, Wegovy’s Lilly & Co. competitor, can be on the record, at $299.)
Stress has been constructing on Novo and Lilly to decrease the U.S. value of their GLP-1 medicine. The compounds have misplaced patent safety in India, and strain from prospects shopping for abroad will possible enhance when generic Wegovy goes on sale in Canada, for as little as $73 a month, probably this 12 months.
In the US, in the meantime, dozens of patents ought to maintain Wegovy generics off the market till 2039, stated professor Robin Feldman, a patent professional on the College of California Regulation-San Francisco. A latest report from the analysis group I-Mak delved into a number of methods patent manipulation retains generics off the U.S. market lengthy after they’re accessible in European nations and Canada.
And whereas the Trump administration has vowed to approve biosimilars extra quickly to make sure extra competitors and decrease costs, that won’t have a lot influence. The massive hurdle in getting generics and biosimilars to market is usually not FDA approval, however the time it takes to override the thickets of patents that U.S. legislation permits producers to deploy to guard their mental property.
For instance, in 2021, the FDA authorized a generic of Otezla, a preferred drug for psoriatic arthritis, but it surely is not going to hit the market till 2028. Its entry would require drugmakers to pay rebates to Medicare in the event that they charged this system greater than different developed nations for “single supply” medicine and biologics. That might basically enable the Medicare program to piggyback on different nations that negotiate the costs of a number of the most costly medicines. These packages are nonetheless going by the rulemaking course of and, once more, would profit solely these coated by the Medicare program and solely not directly.
The common patient-consumer, if keen to pay money, might discover some bargains. However getting the very best deal might take quite a lot of mixing and matching, forcing sufferers to change into picky consumers, eyeing offers for important medicines as they’d for a carton of milk or eggs.
Knowledge reporter Maia Rosenfeld contributed to this text.
